Mannkind (MNKD) Income from Continuing Operations (2010 - 2026)
Mannkind's (MNKD) quarterly Income from Continuing Operations came in at 16619000.0 in Q1 2026, down 226.3% year-on-year from 13158000.0 in Q1 2025, and down 4.21% on a QoQ basis from 15948000.0 in Q4 2025.
Mannkind (MNKD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Income from Continuing Operations data on file, last reported at 16619000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 226.3% year-over-year to 16619000.0 in Q1 2026; TTM through Mar 2026 was 23946000.0, a 179.47% decrease from a year earlier, with the FY2025 full-year figure at 5863000.0, down 78.75% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 16619000.0, down from 15948000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for MNKD reached as high as 13158000.0 in Q1 2025 and fell as low as 29023000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 4853882.35 across 5 years, with a median of 1991000.0 in 2024.
- Across the five-year window, Income from Continuing Operations soared 571.12% in 2024 and sank 315.08% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 17947000.0 in 2022, then jumped by 107.84% to 1407000.0 in 2023, then soared by 427.01% to 7415000.0 in 2024, then sank by 315.08% to 15948000.0 in 2025, then fell by 4.21% to 16619000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 16619000.0 in Q1 2026, 15948000.0 in Q4 2025, and 7981000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn | -16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.62 Mn |
| Dec 31, 2025 | -15.95 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 640,000.00 |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | 11.55 Mn |
| Jun 30, 2024 | -1.99 Mn |
| Mar 31, 2024 | 10.63 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |
| Jun 30, 2021 | -35.52 Mn |